Mucosal vaccination against tuberculosis using inert bioparticles

Infection and Immunity

Volumn 81, Issue 11, 2013, Pages 4071-4080

  Reljic, Rajko ^a   Sibley, Laura ^b   Huang, Jen Min ^b   Pepponi, Ilaria ^a   Hoppe, Andreas ^c   Hong, Huynh A ^b   Cutting, Simon M ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CRYSTALLIN; BCG VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MYCOBACTERIUM ANTIGEN; PENICILLIN DERIVATIVE; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; STREPTOMYCIN;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BACTERIAL SPORE; BIOTECHNOLOGICAL PROCEDURES; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LUNG; MACROPHAGE; MATERIAL COATING; MOUSE; MUCOSAL VACCINATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SPLEEN; T LYMPHOCYTE; TUBERCULOSIS; TUBERCULOSIS CONTROL; VACCINATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, MUCOSAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; CELL SURFACE DISPLAY TECHNIQUES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; LUNG; MALE; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; SPLEEN; SPORES, BACTERIAL; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 84886776623     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00786-13     Document Type: Article

References (38)

1. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, Team MATS. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381:1021-1028.
2. Agger EM, Andersen P. 2002. A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine 21:7-14.
3. Checkley AM, McShane H. 2011. Tuberculosis vaccines: progress and challenges. Trends Pharm. Sci. 32:601-606.
4. Scanga CA, Flynn JL. 2010. Mycobacterial infections and the inflammatory seesaw. Cell Host Microbe 7:177-179.
5. Huang JM, Hong HA, Van Tong H, Hoang TH, Brisson A, Cutting SM. 2010. Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine 28:1021-1030.
6. Song M, Hong HA, Huang JM, Colenutt C, Khang DD, Nguyen TV, Park SM, Shim BS, Song HH, Cheon IS, Jang JE, Choi JA, Choi YK, Stadler K, Cutting SM. 2012. Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1 vaccine. Vaccine 30:3266-3277.
7. Hamasur B, Haile M, Pawlowski A, Schroder U, Kallenius G, Svenson SB. 2004. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin. Exp. Immunol. 138:30-38.
8. Glatman-Freedman A. 2006. The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy. Tuberculosis (Edinb.) 86:191-197.
9. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. 2007. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb.) 87:257-266.
10. Hong HA, Khaneja R, Tam NM, Cazzato A, Tan S, Urdaci M, Brisson A, Gasbarrini A, Barnes I, Cutting SM. 2009. Bacillus subtilis isolated from the human gastrointestinal tract. Res. Microbiol. 160:134-143.
11. Isticato R, Di Mase DS, Mauriello EM, De Felice M, Ricca E. 2007. Amino terminal fusion of heterologous proteins to CotC increases display efficiencies in the Bacillus subtilis spore system. Biotechniques 42:151-152, 154, 156.
12. Nicholson WL, Setlow P. 1990. Sporulation, germination and outgrowth, p 391-450. In Harwood CR, Cutting SM (ed), Molecular biological methods for Bacillus. John Wiley & Sons Ltd., Chichester, United Kingdom.
13. Pepponi I, Stylianou E, van Dolleweerd C, Diogo GR, Paul MJ, Drake PM, Ma JK, Reljic R. 2013. Immune-complex mimics as a molecular platform for adjuvant-free vaccine delivery. PLoS One 8: e60855 doi:10 .1371/journal.pone.0060855.
14. Sharpe SA, McShane H, Dennis MJ, Basaraba RJ, Gleeson F, Hall G, McIntyre A, Gooch K, Clark S, Beveridge NE, Nuth E, White A, Marriott A, Dowall S, Hill AV, Williams A, Marsh PD. 2010. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin. Vaccine Immunol. 17:1170-1182.
15. Yu LH, Cutting SM. 2009. The effect of anti-spore antibody responses on the use of spores for vaccine delivery. Vaccine 27:4576-4584.
16. Chadwick S, Kriegel C, Amiji M. 2010. Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. 62:394-407.
17. Yang W, Peters JI, Williams RO, III. 2008. Inhaled nanoparticles-a current review. Int. J. Pharm. 356:239-247.
18. Behr MA, Small PM. 1999. A historical and molecular phylogeny of BCG strains. Vaccine 17:915-922.
19. Delogu G, Howard A, Collins FM, Morris SL. 2000. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect. Immun. 68:3097- 3102.
20. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, Ottenhoff TH, Klein MR, Huygen K. 2007. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNAvaccinated and tuberculosis-infected mice. Infect. Immun. 75:941-949.
21. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72:6148-6150.
22. Hong HA, Duc le H, Cutting SM. 2005. The use of bacterial spore formers as probiotics. FEMS Microbiol. Rev. 29:813-835.
23. Vajdy M, O'Hagan DT. 2001. Microparticles for intranasal immunization. Adv. Drug Deliv. Rev. 51:127-141.
24. Eyles JE, Williamson ED, Alpar HO. 1999. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. Int. J. Pharm. 189:75-79.
25. Kuper CF, Koornstra PJ, Hameleers DM, Biewenga J, Spit BJ, Duijvestijn AM, van Breda Vriesman PJ, Sminia T. 1992. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13:219-224.
26. Behrens I, Pena AI, Alonso MJ, Kissel T. 2002. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 19:1185-1193.
27. Barnes AG, Cerovic V, Hobson PS, Klavinskis LS. 2007. Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen. Eur. J. Immunol. 37:1538- 1547.
28. Peter K, Men Y, Pantaleo G, Gander B, Corradin G. 2001. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine 19:4121-4129.
29. Yan M, Peng J, Jabbar IA, Liu X, Filgueira L, Frazer IH, Thomas R. 2004. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 324:297-310.
30. Sanders MT, Brown LE, Deliyannis G, Pearse MJ. 2005. ISCOM-based vaccines: the second decade. Immunol. Cell Biol. 83:119-128.
31. Raychaudhuri S, Rock KL. 1998. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol. 16:1025-1031.
32. Korbel DS, Schneider BE, Schaible UE. 2008. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 10:995-1004.
33. Pulendran B, Ahmed R. 2006. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124:849-863.
34. Song JM, Hossain J, Yoo DG, Lipatov AS, Davis CT, Quan FS, Chen LM, Hogan RJ, Donis RO, Compans RW, Kang SM. 2010. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405:165-175.
35. Lee S, Belitsky BR, Brown DW, Brinker JP, Kerstein KO, Herrmann JE, Keusch GT, Sonenshein AL, Tzipori S. 2010. Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine 28:6658-6665.
36. Rouanet C, Debrie AS, Lecher S, Locht C. 2009. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect. 11:995-1001.
37. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. 2006. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette- Guerin immunity. J. Immunol. 177:6353-6360.
38. Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ, Orme IM, Skeiky YA, Alderson MR, Cowgill KD, Prieels JP, Abalos RM, Dubois MC, Cohen J, Mettens P, Lobet Y. 2009. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl. Acad. Sci. U. S. A. 106:2301-2306.